DDInter776 DDInter119
Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Formoterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Isoprenaline
Formoterol {u} (Compound) resembles {v} (Compound) Fenoterol
Formoterol {u} may lead to a major life threatening interaction when taken with {v} Labetalol
Formoterol {u} (Compound) resembles {v} (Compound) Arbutamine
Formoterol {u} (Compound) treats {v} (Disease) chronic obstructive pulmonary disease
Formoterol {u} (Compound) binds {v} (Gene) ADRB1
Formoterol {u} (Compound) upregulates {v} (Gene) HMOX1
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Formoterol {u} (Compound) downregulates {v} (Gene) RPS4Y1
Formoterol {u} (Compound) causes {v} (Side Effect) Anxiety
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Formoterol (Compound) resembles Fenoterol (Compound)
Formoterol may lead to a major life threatening interaction when taken with Labetalol
Formoterol (Compound) resembles Arbutamine (Compound)
Formoterol (Compound) treats chronic obstructive pulmonary disease (Disease)
Formoterol (Compound) binds ADRB1 (Gene)
Formoterol (Compound) upregulates HMOX1 (Gene)
Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Formoterol (Compound) downregulates RPS4Y1 (Gene)
Formoterol (Compound) causes Anxiety (Side Effect)